Mohammad Krayem (Mohamad Krayem)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 15

Top Venues

Cancers

Cells

Biology

Université Libre de Bruxelles

Université Libre de Bruxelles Faculté de Pharmacie (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Université Libre de Bruxelles Oct 01 2010

Belgium

Senior Researcher :: Jules Bordet Institute

Education History

Université Libre de Bruxelles Faculté de Pharmacie

Belgium

PHD

Publications

Mohammad Krayem, Philippe Aftimos, Ahmad Najem, Tim van den Hooven, Adriënne van den Berg, Liesbeth Hovestad-Bijl, Rik de Wijn, Riet Hilhorst, Rob Ruijtenbeek, Malak Sabbah, Joseph Kerger, Ahmad Awada, Fabrice Journe, Ghanem E Ghanem
Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers 2020, 12 , 512. Cancers 16 (14) (2024)
Mohammad Krayem, Philippe Aftimos, Ahmad Najem, Tim van den Hooven, Adriënne van den Berg, Liesbeth Hovestad-Bijl, Rik de Wijn, Riet Hilhorst, Rob Ruijtenbeek, Malak Sabbah, Joseph Kerger, Ahmad Awada, Fabrice Journe, Ghanem E Ghanem
Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers 2020, 12 , 512. Cancers 16 (14) (2024)
Mohammad Krayem, Philippe Aftimos, Ahmad Najem, Tim van den Hooven, Adriënne van den Berg, Liesbeth Hovestad-Bijl, Rik de Wijn, Riet Hilhorst, Rob Ruijtenbeek, Malak Sabbah, Joseph Kerger, Ahmad Awada, Fabrice Journe, Ghanem E Ghanem
Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers 2020, 12 , 512. Cancers 16 (14) (2024)
Ahmad Najem, Mohammad Krayem, Serena Sabbah, Matilde Pesetti, Fabrice Journe, Ahmad Awada, Laurent Désaubry, Ghanem E Ghanem
Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies. Cells 12 (14) (2023)
Mohammad Krayem, Malak Sabbah, Ahmad Najem, An Wouters, Filip Lardon, Stephane Simon, François Sales, Fabrice Journe, Ahmad Awada, Ghanem E Ghanem, Dirk Van Gestel
Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11 , 1093. Cancers 15 (24) (2023)
Mohammad Krayem, Malak Sabbah, Ahmad Najem, An Wouters, Filip Lardon, Stephane Simon, François Sales, Fabrice Journe, Ahmad Awada, Ghanem E Ghanem, Dirk Van Gestel
Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11 , 1093. Cancers 15 (24) (2023)
Pashalina Kehagias, Nadège Kindt, Mohammad Krayem, Ahmad Najem, Giulia Agostini, Elena Acedo Reina, Giacomo Bregni, Francesco Sclafani, Fabrice Journe, Ahmad Awada, Ghanem E Ghanem, Alain Hendlisz
Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance. Cells 11 (22) (2022)
Hamza Alghamdi, Jennifer Dhont, Mohammad Krayem, Pauline De Bruyn, Benedikt Engels, Dirk Van Gestel, Robbe Van den Begin
The Road to Dissemination: The Concept of Oligometastases and the Barriers for Widespread Disease. Cancers 14 (8) (2022)
Ahmad Najem, Laura Soumoy, Malak Sabbah, Mohammad Krayem, Ahmad Awada, Fabrice Journe, Ghanem E Ghanem
Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma. Cells 11 (7) (2022)
Malak Sabbah, Ahmad Najem, Mohammad Krayem, Ahmad Awada, Fabrice Journe, Ghanem E Ghanem
RTK Inhibitors in Melanoma: From Bench to Bedside. Cancers 13 (7) (2021)
Laura Soumoy, Corentin Schepkens, Mohammad Krayem, Ahmad Najem, Vanessa Tagliatti, Ghanem E Ghanem, Sven Saussez, Jean-Marie Colet, Fabrice Journe
Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis. Cancers 12 (5) (2020)
Mohammad Krayem, Philippe Aftimos, Ahmad Najem, Tim van den Hooven, Adriënne van den Berg, Liesbeth Hovestad-Bijl, Rik de Wijn, Riet Hilhorst, Rob Ruijtenbeek, Malak Sabbah, Joseph Kerger, Ahmad Awada, Fabrice Journe, Ghanem E Ghanem
Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. Cancers 2020, 12, 512. Cancers 12 (10) (2020)
Mohammad Krayem, Philippe Aftimos, Ahmad Najem, Tim van den Hooven, Adriënne van den Berg, Liesbeth Hovestad-Bijl, Rik de Wijn, Riet Hilhorst, Rob Ruijtenbeek, Malak Sabbah, Joseph Kerger, Ahmad Awada, Fabrice Journe, Ghanem E Ghanem
Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers 12 (2) (2020)
Laura Soumoy, Mathilde Wells, Ahmad Najem, Mohammad Krayem, Ghanem Ghanem, Stéphanie Hambye, Sven Saussez, Bertrand Blankert, Fabrice Journe
Toad Venom Antiproliferative Activities on Metastatic Melanoma: Bio-Guided Fractionation and Screening of the Compounds of Two Different Venoms. Biology 9 (8) (2020)
Mohammad Krayem, Malak Sabbah, Ahmad Najem, An Wouters, Filip Lardon, Stephane Simon, François Sales, Fabrice Journe, Ahmad Awada, Ghanem E Ghanem, Dirk Van Gestel
The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 11 (8) (2019)

Mohammad Krayem.css-eqlu8i{font-size:small;padding-left:4px;} (Mohamad Krayem)

Publication Activity (10 Years)

Top Topics

Top Venues

Mohammad Krayem (Mohamad Krayem)